Expression of cyclin D1 and GSK-3β and their predictive value of prognosis in squamous cell carcinomas of the tongue

被引:60
作者
Goto, H
Kawano, K
Kobayashi, I
Sakai, H
Yanagisawa, S
机构
[1] Oita Med Univ, Dept Oral & Maxillofacial Surg, Fac Med, Oita 8795593, Japan
[2] Univ Kyusyu, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral Diagnost Sci,Higashi Ku, Fukuoka 8128582, Japan
[3] Univ Kyusyu, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral Pathol & Med,Higashi Ku, Fukuoka 8128582, Japan
来源
ORAL ONCOLOGY | 2002年 / 38卷 / 06期
关键词
cyclin D1; overexpression; gene amplification; GSK-3; beta; squamous cell carcinoma; tongue;
D O I
10.1016/S1368-8375(01)00121-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The status of cyclin D1 and glycogen synthase kinase 3beta (GSK-3beta) was investigated in 41 patients with T1 and T2 squamous cell carcinomas (SCCs) of the tongue. Out of the 41 SCCs, 27 (65.9%) showed overexpression of cyclin D1 in comparison with normal lingual epithelia by an immunohistochemical method. Cyclin D1 gene amplification was detected in only two (9.1%) of 22 informative cases of the SCCs by differential PCR. Expression of GSK-3beta, which was found to regulate proteosomal degradation of cyclin D1 protein, was reduced in 16 cases (39.0%) of the SCCs relative to normal epithelia, and the intensity of GSK-3beta staining showed an inverse association with cyclin D1. These findings suggest that overexpression of cyclin D1 primarily results from stabilization due to reduction of GSK-3beta, but not cyclin D1 gone amplification, in lingual SCCs. Kaplan-Meier analysis demonstrated that the patients with high cyclin D1 and reduced GSK-3beta expression had a significantly lower 5-year survival than the patients with low cyclin D1 and non-reduced GSK-3beta expression (P = 0.014). The cyclin D1 and GSK-3beta coupled assessment was more valuable for the prediction of prognosis than assessment based on cyclin D1. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:549 / 556
页数:8
相关论文
共 33 条
[1]  
Akervall JA, 1997, CANCER, V79, P380
[2]  
BARTKOVA J, 1995, CANCER RES, V55, P949
[3]  
BATSAKIS JG, 1974, TUMORS HEAD NECK CLI
[4]  
Bova RJ, 1999, CLIN CANCER RES, V5, P2810
[5]  
CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO
[6]  
2-K
[7]   Glycogen synthase kinase 3β regulates cyclin D1 proteolysis and subcellular localization [J].
Diehl, JA ;
Cheng, MG ;
Roussel, MF ;
Sherr, CJ .
GENES & DEVELOPMENT, 1998, 12 (22) :3499-3511
[8]  
Gansauge S, 1997, CANCER RES, V57, P1634
[9]  
JAKOBSSON PA, 1973, ACTA RADIOL THER PHY, V12, P1
[10]  
JARES P, 1994, CANCER RES, V54, P4813